Wockhardt share price

High risk
  • 58%Low risk
  • 58%Moderate risk
  • 58%Balanced risk
  • 58%High risk
  • 58%Extreme risk
  • 1,320.30(-1.50%)
    May 22, 2025 15:29:45 PM IST
    • NSE
    • BSE
  • Vol : 344.34K (NSE + BSE)
    Last 20 day avg : 460.04 K

Wockhardt is trading -1.50% lower at Rs 1,320.30 as compared to its last closing price. Wockhardt has been trading in the price range of 1,345.00 & 1,298.45. Wockhardt has given -6.82% in this year & 2.87% in the last 5 days. The company posted a net profit of 13.00 Crores in its last quarter.Listed peers of Wockhardt include Gland Pharma (-1.92%), Syngene International (-0.40%), Wockhardt (-1.50%).The Mutual Fund holding in Wockhardt was at 7.56% in 31 Mar 2025. The MF holding has increased from the last quarter. The FII holding in Wockhardt was at 6.81% in 31 Mar 2025. The FII holding has increased from the last quarter.

  • Overview
  • Financials
  • Forecast
  • Technical Analysis
  • Peers
  • Shareholding
  • About the company
  • FAQ

Overview

  • 1 D
  • 5 D
  • 1 M
  • 3 M
  • 6 M
  • 1 Y
  • 5 Y
  • MAX
Key Metrics

Updated on May 23, 2025, 02:53 AM UTC

  • Dividend Yield
    Annual dividends as a percentage of the stock price.
    0.00
    Lower than industry
  • P/B
    The P/B ratio shows how a stock's market price compares to its book value. It helps gauge whether a stock is undervalued or overvalued relative to its net assets.
    6.03
    Higher than historical values
  • P/E
    Price-to-earnings ratio based on trailing 12-month earnings
    0.00
    Higher than historical values
  • Beta
    Beta measures a stock's volatility compared to the overall market. A beta > 1 indicates higher volatility than the market.
    1.88
    High volatility
  • Debt To Equity
    The debt-to-equity ratio, indicating a company's financial leverage.
    0.70
    Higher than industry
  • PEG Ratio
    The PEG ratio evaluates a stock's valuation by comparing its P/E ratio to its earnings growth rate. A lower PEG suggests better value relative to growth
    -
Price range
Day Range
Lowest
1,298.45
Highest
1,345.00
52 week range
Lowest
489.20
Highest
1,678.60
Wockhardt Financials
Financials
Financials include key reports like the Profit & Loss Statement (P&L), Balance Sheet, and Cash Flow Statement, providing insights into a company's performance, financial health, and liquidity
View all
  • Income
  • Balance Sheet
  • Cash Flow
Loading...
Units in the chart are in crores
Insights
  • Financial
  • Valuation
    • financial-insightsCompany is profitable
    • financial-insightsThe company's revenue grew in December quarter by 2.85% from Rs 721.00 crore to Rs 701.00 crore, year-on-year
    • financial-insightsCompany has registered a profit of 13.00 cr vs a loss of 83.00 cr in the same quarter last year.
    • financial-insightsThe debt to equity of the company is higher than the industry median
    • financial-insightsEarnings are insufficient to cover the interest expenses on outstanding debt
Wockhardt Technical Analysis
Pivot Level - classic
Info
Key price levels (support and resistance) calculated using the previous day's high, low, and close, aiding in technical analysis and trading decisions
  • R1
  • 1,396.85
  • R2
  • 1,497.00
  • R3
  • 1,600.00
Pivot1,293.85
  • S1
  • 1,193.70
  • S2
  • 1,090.70
  • S3
  • 990.55
Short Term
Info
Considers price movement over the last 1-2 weeks
Not Available
Long Term
Info
Considers price movement over the last 6 months
Not Available
  • Very Bearish
  • Bearish
  • Neutral
  • Very Bullish
  • Bullish
Trends unavailable at the moment.
Wockhardt Peers
Return Comparison
Peers Comparison
Names
Technical ratingPrice%ChangeMarket CapP/EP/BDividend YieldDebt to Equity
Gland Pharma
Neutral
1,542.35-1.9225,411.2137.062.831.151.17
Syngene International
Bearish
636.45-0.4025,619.4654.455.430.208.65
Wockhardt
Neutral
1,320.30-1.5021,485.76-6.13-31.59
Eris Lifesciences
Bullish
1,519.500.9720,666.5358.357.190.4962.42
Alembic Pharmaceuticals
Moderately Bullish
962.700.0918,939.8733.013.641.140.90
Wockhardt Shareholding
View All
Shareholding Pattern
Breakdown of a company's ownership structure, showing stakes held by Promoters, Mutual Funds, FII(s) & Others.
    No Data
    Shareholding pattern for Wockhardt is currently unavailable
    Please check back later.
    Shareholding Insights
    • InsightsPledged found - Promoter(s) have pledged 18.24% of shares.
    • InsightsPromoter(s) have increased pledged shares to 16.98% from 18.24% earlier.
    • InsightsPromoter(s) holding is moderate at 49.09%
    • InsightsPromoter(s) have decreased the stake in the company in last 12 months
    • InsightsFIIs are invested in this company
    • InsightsFIIs holding has increased by 0.28 percentage points from previous quarter
    • InsightsMutual Funds holding has increased by 0.43 percentage points from previous quarter
    Mutual Fund Ownership
    View all
    Samco Active Momentum Fund Regular Growth
    NA
    • Amount Invested (Cr.) 40.85
    • % of AUM 4.75
    ITI Focused Equity Fund Regular Growth
    NA
    • Amount Invested (Cr.) 19.29
    • % of AUM 3.92
    Tata India Pharma & Healthcare Fund Regular Growth
    NA
    • Amount Invested (Cr.) 35.65
    • % of AUM 2.92
    HDFC Pharma and Healthcare Fund Regular Growth
    NA
    • Amount Invested (Cr.) 44.52
    • % of AUM 2.67
    Tata Small Cap Fund Regular Growth
    3/5
    • Amount Invested (Cr.) 233.80
    • % of AUM 2.48
    Wockhardt Corporate Actions
    View all
    • Board Meetings
    • AGM
    • Dividends
    • Bonus
    • Split
    • Rights
    Meeting DatePurpose
    2025-02-07Quarterly Results
    2024-11-13Quarterly Results
    2024-08-09Quarterly Results
    2024-05-28Audited Results
    2024-03-26Others
    About the company Wockhardt
    • IndustryBiotechnology & Drugs
    • ISININE049B01025
    • BSE Code532300
    • NSE CodeWOCKPHARMA
    Wockhardt Limited is a research-based global pharmaceutical and biotech company. The Company is engaged in the pharmaceutical business. It focuses on the unmet need for antibacterial drugs that are effective against the menace of untreatable superbugs. It manufactures and supplies branded and generic finished formulations, as well as intermediate products like active pharmaceutical ingredients (APIs), worldwide. The Company’s products in India include EMROK, MERIWOK, REINVEXIN, ERLISO, METHYCOBAL TABLET, METHYCOBAL INJ, METHYCOBAL D, HAPID, PROXYFEN NANO GEL, LIVATIRA TABLET, LIVATIRA INJ, GABAWOK NT 100, GABAWOK NT 400, ETOBRIX 90, ETOBRIX TH4, ETOBRIX P, GLARZEN CARTRIDGE, GLARZEN DISPOPEN 2, ESOWOK D, TERITIDE, GLIMADAY, SITAWOK, GLARITUS, TRIMETADAY, MOPADAY, INOGLA, and ZINODAP. The Company has manufacturing and research facilities in India, United States of America and the United Kingdom and a manufacturing facility in Ireland.
    • Management Info
    • Habil Fakhruddin KhorakiwalaExecutive Chairman of the Board
    • Deepak MadnaniChief Financial Officer
    • Rashmi MamturaCompliance Officer, Company Secretary
    • Murtaza Habil KhorakiwalaManaging Director, Executive Director
    • Huzaifa Habil KhorakiwalaExecutive Director
    Wockhardt Share Price FAQs

    Wockhardt is trading at 1320.30 as on Thu May 22 2025 09:59:45. This is -1.50% lower as compared to its previous closing price of 1340.40.

    The market capitalization of Wockhardt is 21485.76 Cr as on Thu May 22 2025 09:59:45.

    The 52 wk high for Wockhardt is 1678.60 whereas the 52 wk low is 489.20

    Wockhardt can be analyzed on the following key metrics -

    • TTM P/E:
    • Sector P/E: 25.03
    • Dividend Yield: 0.00%
    • D/E ratio: -

    Wockhardt reported a net profit of -463.00 Cr in 2024.

    The Mutual Fund Shareholding was 7.56% at the end of 31 Mar 2025.